Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Innere Medizin
Erschienen in: Die Innere Medizin 12/2023

10.11.2023 | Apoplex | CME

Sekundärprophylaxe des ischämischen Schlaganfalls

verfasst von: Dr. med. Moritz Schmidbauer, Dr. med. Johannes Wischmann, Prof. Dr. Konstantinos Dimitriadis, Prof. Dr. Lars Kellert

Erschienen in: Die Innere Medizin | Ausgabe 12/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Sekundärprophylaxe ischämischer Schlaganfälle bietet ein enormes therapeutisches Potenzial, einerseits wegen der Häufigkeit von Rezidiven, andererseits aufgrund der herausragenden Bedeutung der modifizierbaren kardiovaskulären Risikofaktoren für das individuelle Schlaganfallrisiko. Dabei sind die antithrombotischen, interventionellen und operativen Therapiemöglichkeiten anhand der jeweiligen Ätiologie auszuwählen und die Risikofaktoren zielgerecht zu optimieren. Insbesondere in der Langzeitbehandlung ist eine enge interdisziplinäre und intersektorale Zusammenarbeit erforderlich.
Literatur
1.
Kyu HH et al (2018) Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1859–1922CrossRef
2.
Palm F et al (2010) Stroke incidence and survival in Ludwigshafen am Rhein, Germany: The Ludwigshafen Stroke Study (LuSSt). Stroke 41:1865–1870PubMedCrossRef
3.
Rki Gesundheitsberichterstattung des Bundes gemeinsam getragen von RKI und DESTATIS Gesundheit in Deutschland
4.
Berghout BP, Bos D, Koudstaal PJ, Ikram MA, Ikram MK (2023) Risk of recurrent stroke in Rotterdam between 1990 and 2020: a population-based cohort study. Lancet Reg Health Eur 30:
5.
Flach C, Muruet W, Wolfe CDA, Bhalla A, Douiri A (2020) Risk and secondary prevention of stroke recurrence: a population-base cohort study. Stroke 51:2435–2444PubMedPubMedCentralCrossRef
6.
O’Donnell MJ et al (2016) Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 388:761–775PubMedCrossRef
7.
Adams HP et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41PubMedCrossRef
8.
Hart RG et al (2014) Embolic strokes of undetermined source: The case for a new clinical construct. Lancet Neurol 13:429–438PubMedCrossRef
9.
10.
11.
Wang Y et al (2013) Clopidogrel with Aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369:11–19PubMedCrossRef
12.
Johnston SC et al (2020) Ticagrelor and Aspirin or Aspirin alone in acute ischemic stroke or TIA. N Engl J Med 383:207–217PubMedCrossRef
13.
14.
CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339CrossRef
15.
Chi NF et al (2018) Comparison between aspirin and clopidogrel in secondary stroke prevention based on real-world data. J Am Heart Assoc 7:
16.
Serebruany VL, Alberts MJ, Hanley DF (2008) Prasugrel in the Poststroke cohort of the TRITON trial: the clear and present danger. Cerebrovasc Dis 26:93–94PubMedCrossRef
17.
Kim SM, Jung J‑M, Kim BJ, Lee J‑S, Kwon SU (2019) Cilostazol mono and combination treatments in Ischemic stroke. Stroke 50:3503–3511PubMedCrossRef
18.
Rothwell PM et al (2018) Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 392:387–399PubMedPubMedCentralCrossRef
19.
Hamann GF, Sander D, Grau A, Röther J (2022) S2k-Leitlinie: Sekundärprophylaxe ischämischer Schlaganfall und transitorische ischämische Attacke (TIA) – Teil 1 und Teil 2. DGNeurologie 5:369–380CrossRef
20.
Su T‑H et al (2016) To load or not to load? Aspirin loading in acute Ischemic stroke: a study of clinical outcomes. J Stroke Cerebrovasc Dis 25:2439–2447PubMedCrossRef
21.
Eikelboom JW et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377:1319–1330PubMedCrossRef
22.
Lee M et al (2017) Antiplatelet regimen for patients with breakthrough strokes while on Aspirin. Stroke 48:2610–2613PubMedCrossRef
23.
Li L, Geraghty OC, Mehta Z, Rothwell PM (2017) Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 390:490–499PubMedPubMedCentralCrossRef
24.
Mo C et al (2015) Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol 21:5382–5392PubMedPubMedCentralCrossRef
25.
Madhavan M et al (2019) Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. Am Heart J 211:77–89PubMedCrossRef
26.
Steffel J et al (2016) Edoxaban versus warfarin in atrial fibrillation patients at risk of falling ENGAGE AF-TIMI 48 analysis
27.
Rao MP et al (2018) Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral Anticoagulation: insights from the ARISTOTLE trial. Am J Med 131:269–275.e2PubMedCrossRef
28.
Fischer U et al (2023) Early versus later anticoagulation for stroke with atrial fibrillation. N Engl J Med 388:2411–2421PubMedCrossRef
29.
Hart RG et al (2018) Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 378:2191–2201PubMedCrossRef
30.
Diener H‑C et al (2019) Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 380:1906–1917PubMedCrossRef
31.
ESO (2023) ESOC 2023 – late breaking abstracts. Eur Stroke J 8:670–711CrossRef
32.
Poli S et al (2023) Abstract 31: the ATTICUS randomized controlled trial—Subgroup analyses. Stroke 54:
33.
Tsivgoulis G et al (2022) Prolonged cardiac monitoring and stroke recurrence: a meta-analysis. Neurology 98:E1942–E1952PubMedCrossRef
34.
Tsivgoulis G et al (2023) Prolonged cardiac monitoring for stroke prevention: A systematic review and meta-analysis of randomized-controlled clinical trials. Eur Stroke J 8:106–116PubMedCrossRef
35.
Svendsen JH et al (2021) Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet 398:1507–1516PubMedCrossRef
36.
37.
Kent DM et al (2021) Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke JAMA | original investigation. JAMA 326:2277–2286PubMedPubMedCentralCrossRef
38.
Saver JL, Mattle HP, Thaler D (2018) Patent foramen ovale closure versus medical therapy for cryptogenic ischemic stroke. Stroke 49:1541–1548PubMedCrossRef
39.
Baumgartner RW et al (2001) Carotid dissection with and without ischemic events: Local symptoms and cerebral artery findings. Neurology 57:827–832PubMedCrossRef
40.
41.
Engelter ST et al (2021) Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial. Lancet Neurol 20:341–350PubMedCrossRef
42.
Markus HS, Levi C, King A, Madigan J, Norris J (2019) Antiplatelet therapy vs anticoagulation therapy in cervical artery dissection: The cervical artery dissection in stroke study (cadiss) randomized clinical trial final results. JAMA Neurol 76:657–664PubMedPubMedCentralCrossRef
43.
44.
Nicholls SJ et al (2016) Effect of evolocumab on progression of coronary disease in statin-treated patients. JAMA 316:2373PubMedCrossRef
45.
Lee M et al (2022) Association between intensity of low-density lipoprotein cholesterol reduction with statin-based therapies and secondary stroke prevention a meta-analysis of randomized clinical trials. JAMA Neurol 79:349–358PubMedPubMedCentralCrossRef
46.
Koskinas KC et al (2018) Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J 39:1172–1180PubMedCrossRef
47.
Mach F et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188PubMedCrossRef
48.
Amarenco P et al (2020) A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med 382:9–19PubMedCrossRef
49.
Amarenco P et al (2020) Benefit of targeting a LDL (Low-Density Lipoprotein) cholesterol <70 mg/dL during 5 years after ischemic stroke. Stroke 51:1231–1239PubMedCrossRef
50.
Kleindorfer DO et al (2021) 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 52:e364–e467PubMedCrossRef
51.
Giugliano RP et al (2020) Stroke prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke 51:1546–1554PubMedCrossRef
52.
Ray KK et al (2020) Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol. N Engl J Med 382:1507–1519PubMedCrossRef
53.
Lewington S et al (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903–1913PubMedCrossRef
54.
PROGRESS Collaborative Group. (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033–1041CrossRef
55.
Kitagawa K et al (2019) Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol 76:1309–1318PubMedPubMedCentralCrossRef
56.
57.
SPS3 Study Group et al (2013) Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 382:507–515CrossRef
58.
Bath PM et al (2017) Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke: main results from the pilot ‘prevention of decline in cognition after stroke trial’ (PODCAST) Randomised controlled trial. PLoS ONE 12:e164608PubMedPubMedCentralCrossRef
59.
Beddhu S et al (2018) Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control. Circulation 137:134–143PubMedCrossRef
60.
Zonneveld TP et al (2018) Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev 7:CD7858PubMed
61.
Buse JB (2007) Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol 99:S21–S33CrossRef
62.
The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRef
63.
Lee M, Saver JL, Liao HW, Lin CH, Ovbiagele B (2017) Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis. Stroke 48:388–393PubMedCrossRef
64.
Schmidbauer ML, Wollenweber FA (2020) Diabetes and stroke. Diabetologe 16:535–544CrossRef
65.
Feigin VL et al (2016) Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol 15:913–924PubMedCrossRef
66.
67.
68.
Aldoori MI, Rahman SH (1998) Smoking and stroke: a causative role. Heavy smokers with hypertension benefit most from stopping. BMJ 317:962–963PubMedPubMedCentralCrossRef
69.
Schwarzbach CJ et al (2023) The structured ambulatory post-stroke care program for outpatient aftercare in patients with ischaemic stroke in Germany (SANO): an open-label, cluster-randomised controlled trial. Lancet Neurol 22:787–799PubMedCrossRef
70.
Ahmadi M et al (2020) A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPiRE-TMS): an open-label, randomised controlled trial. Lancet Neurol 19:49–60PubMedCrossRef
71.
Willeit P et al (2020) STROKE-CARD care to prevent cardiovascular events and improve quality of life after acute ischaemic stroke or TIA: A randomised clinical trial. EClinicalMedicine 25:100476PubMedPubMedCentralCrossRef
72.
Metadaten
Titel
Sekundärprophylaxe des ischämischen Schlaganfalls
verfasst von
Dr. med. Moritz Schmidbauer
Dr. med. Johannes Wischmann
Prof. Dr. Konstantinos Dimitriadis
Prof. Dr. Lars Kellert
Publikationsdatum
10.11.2023

Weitere Artikel der Ausgabe 12/2023

Die Innere Medizin 12/2023 Zur Ausgabe

Einführung zum Thema

Was ist gesichert in der Therapie?

Schwerpunkt: Was ist gesichert in der Therapie?

Was ist gesichert in der Therapie des ischämischen Schlaganfalls?

Schwerpunkt: Was ist gesichert in der Therapie?

Was ist gesichert in der Therapie der Zöliakie?

Mitteilungen des BDI

Praxenkollaps

Fortbildungen und Kongresse des BDI

Fortbildungen und Kongresse des BDI

Schwerpunkt: Was ist gesichert in der Therapie?

Was ist gesichert in der Prävention, Diagnostik und Therapie des frühen Mammakarzinoms?
Bildnachweise